<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156698</url>
  </required_header>
  <id_info>
    <org_study_id>zhouliang</org_study_id>
    <nct_id>NCT04156698</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, multidisciplinary, open-label, single-arm prospective clinical&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 51 patients with hypohparyngeal carcinoma will be enrolled, These patients who&#xD;
      have locally advanced-stage disease, including TNM stage cT3-4N1-2M0 and require a total&#xD;
      laryngectomy as an initial therapy. Patients who achieved a CR or PR at the primary site&#xD;
      after three cycles of TPF-regimen chemotherapy combined with immuotherapy will be referred&#xD;
      for definitive RT and immuotherapy, while patients who received an evaluation of PD or SD at&#xD;
      the primary site were referred for surgery followed by adjuvant RT/CRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>until 3 months after therapy</time_frame>
    <description>Proportion of patients with partial or complete response in tumor burden as defined by RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPR</measure>
    <time_frame>3 years</time_frame>
    <description>Larynx preservation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFS</measure>
    <time_frame>3 years</time_frame>
    <description>Metastasis free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Hypopharyngeal Carcinoma</condition>
  <condition>Immunotherapy</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:&#xD;
Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;&#xD;
Radical radiotherapy followed by concurrent immunotherapy:&#xD;
Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;&#xD;
Maintenance period:&#xD;
After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w and apatinib 250 mg d1-5 qw will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is a chemotherapy drug.</description>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <other_name>Docetaxel (domestic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is a chemotherapy drug.</description>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <other_name>chemotherapy drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine is a chemotherapy drug.</description>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <other_name>chemotherapy drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.</description>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <other_name>Anti-PD-1 Antibody (Jiangsu Hengrui)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib is a selective VEGFR2 inhibitor.</description>
    <arm_group_label>Camrelizumab (PD-1 inhibitor) group</arm_group_label>
    <other_name>VEGFR2 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients have histologically confirmed hypopharyngeal squamous cell carcinoma and&#xD;
             require total laryngectomy, including the piriform fossa, postcricoid region, and&#xD;
             posterior pharyngeal wall with TNM stage cT3-4cN1-2M0.&#xD;
&#xD;
          2. Able to understand and willing to sign a written informed consent document.&#xD;
&#xD;
          3. Age≥ 18 and≤ 70 years.&#xD;
&#xD;
          4. Male or female.&#xD;
&#xD;
          5. Performance status of ECOG 0-2.&#xD;
&#xD;
          6. Expected lifetime &gt; 6 months.&#xD;
&#xD;
          7. Normal blood test, hepatic and renal functions. Normal hearing. Blood test:&#xD;
             WBC≥4.0×109/L，ANC≥2.0×109/L，PLT≥100×109/L，HGB≥100g/L；Hepatic function: ALT、AST&lt; upper&#xD;
             limit of normal. Kidney function: Serum creatinine &lt; upper limit of normal value, and&#xD;
             creatinine clearance rate ≥ 60 ml/min（Cockcroft-Gault formula）. Cardiac&#xD;
             ultrasonography left ventricular ejection fraction &gt;50%.&#xD;
&#xD;
          8. No prior allergic reaction to biological agents/Apatinib and/or ingredient in the&#xD;
             drug.&#xD;
&#xD;
          9. No drug abuse.&#xD;
&#xD;
         10. Good compliance.&#xD;
&#xD;
         11. No other important related diseases (such as other tumors, severe heart, lung and&#xD;
             central nervous system diseases, etc.).&#xD;
&#xD;
         12. Negative pregnancy test (for female patients with fertility).&#xD;
&#xD;
         13. Male patients with fertility and female patients with fertility and pregnancy risk&#xD;
             must agree to use contraceptive methods throughout the study period, and continued&#xD;
             until at least 6 months after the last dose of cisplatin and 30 days after the last&#xD;
             dose of PD-1 antibody/placebo (whichever occurs later). Female patients who do not&#xD;
             have fertility (ie meet at least one of the following criteria): Have undergone&#xD;
             hysterectomy and/or bilateral oophorectomy with archival records, medically confirmed&#xD;
             ovarian function decline; In postmenopausal state. It is defined as: At least 12&#xD;
             months of continuous menstruation without other pathological or physiological reasons,&#xD;
             and the status confirmed by serum follicle stimulating hormone (FSH) levels is&#xD;
             consistent with postmenopausal status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with cervical lymph node cN3.&#xD;
&#xD;
          2. Have a history of other cancers in the past five years, radical or untreated prostate&#xD;
             cancer (Gleason score ≤ 6), or complete treatment of breast ductal carcinoma in situ,&#xD;
             except for patients with cured skin basal cell carcinoma or squamous cell skin cancer.&#xD;
&#xD;
          3. Patients with target lesions who have received radiation therapy or surgery (except&#xD;
             biopsy).&#xD;
&#xD;
          4. Patients who have previously used chemotherapy, immunotherapy, or biological targeted&#xD;
             therapy for primary tumors&#xD;
&#xD;
          5. Patients who have participated in other clinical trials within 4 weeks before the&#xD;
             test.&#xD;
&#xD;
          6. Any of the following conditions in the first 6 months of random grouping: myocardial&#xD;
             infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft,&#xD;
             symptomatic congestive heart failure, cerebrovascular accident, patients with&#xD;
             transient ischemic attack or symptomatic pulmonary embolism.&#xD;
&#xD;
          7. Patients with hypertension who cannot control well through single antihypertensive&#xD;
             medication (systolic blood pressure &gt;140 mmHg, diastolic blood pressure &gt;90 mmHg);&#xD;
&#xD;
          8. Patients with grade I or above coronary heart disease, arrhythmia (including men with&#xD;
             a QTc interval &gt;450 ms, women &gt;470 ms), and cardiac insufficiency.&#xD;
&#xD;
          9. Urinary protein was greater than ++ and 24-hour urinary protein quantification &gt;1.0 g.&#xD;
&#xD;
         10. Many factors that affect oral medications (such as inability to swallow, nausea,&#xD;
             vomiting, chronic diarrhea, and intestinal obstruction).&#xD;
&#xD;
         11. Patients with abnormal coagulation function（INR&gt;1.5、APTT&gt;1.5 ULN）and bleeding&#xD;
             tendency.&#xD;
&#xD;
         12. Patients with a history of psychotropic substance abuse that is active or has a mental&#xD;
             disorder.&#xD;
&#xD;
         13. Patients who required systemic treatment with corticosteroids (&gt;10 mg prednisone&#xD;
             equivalent daily) or other immunosuppressive agents within 2 weeks prior to the first&#xD;
             use of the study drug.&#xD;
&#xD;
         14. Patients with a history of severe allergies or allergies; patients with active&#xD;
             autoimmune diseases that may worsen when receiving immunostimulants; patients with&#xD;
             type 1 diabetes, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism who do not&#xD;
             require immunosuppressive therapy are eligible to participate in the study.&#xD;
&#xD;
         15. Patients who have previously been diagnosed with immunodeficiency or known human&#xD;
             immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related&#xD;
             diseases. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (HBV) surface&#xD;
             antigen is positive at screening, or patients with positive HCV RNA [ribonucleic acid]&#xD;
             when positive for anti-HCV antibody screening test. Patients with a known history of&#xD;
             active tuberculosis (TB).&#xD;
&#xD;
         16. Vaccination within 4 weeks prior to randomization, except for inactivated vaccines.&#xD;
&#xD;
         17. Pregnant or lactating women who are in the reproductive period but have not taken&#xD;
             effective contraceptive measures.&#xD;
&#xD;
         18. The investigator believes that it is inappropriate for individuals to participate in&#xD;
             the trial: having, for example, severe acute or chronic medical conditions (including&#xD;
             immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary&#xD;
             fibrosis) or mental illness (including recent time [within the past year] or active&#xD;
             suicidal ideation or behavior) .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Zhou, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye &amp; ENT Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongli Gong, PhD.</last_name>
    <phone>8621-64377151</phone>
    <email>gonghlent@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shu Tian, PhD.</last_name>
    <phone>8621-64377151</phone>
    <email>tianshueent@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Zhou, PhD.</last_name>
      <phone>8621 64377151</phone>
      <email>zhoulent@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shu Tian, PhD.</last_name>
      <phone>8621 64377151</phone>
      <email>tianshueent@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

